SCHEMBL13408570

SCHEMBL13408570

COC(=O)c1cc([N+](=O)[O-])ccc1S(=O)(=O)Cl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.50
ALDH1A1 P00352 4/20 0.48
VCAM1 P19320 1/20 0.47
LMNA P02545 2/20 0.46
MAPT P10636 4/20 0.44
GAA P10253 1/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA9 Q16790 1/20 0.43
HTT P42858 3/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
RORC P51449 1/20 0.43
CDK1 P06493 1/20 0.43
NPC1 O15118 2/20 0.42
PKM P14618 2/20 0.42
TDP1 Q9NUW8 1/20 0.42
CTSV O60911 1/20 0.42
CTSL P07711 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30047022 1.00 POLB (0.50) POLBALDH1A1VCAM1LMNAMAPT
SCHEMBL29451438 0.89 POLB (0.50) POLBALDH1A1VCAM1LMNAMAPT
SCHEMBL6104167 0.89 POLB (0.50) POLBALDH1A1VCAM1LMNAMAPT
SCHEMBL19071937 0.87 POLB (0.51) POLBALDH1A1VCAM1LMNAMAPT
SCHEMBL12473437 0.82 ALDH1A1 (0.53) ALDH1A1MAPTGAAHTTMEN1
SCHEMBL1403472 0.80 ALDH1A1 (0.56) POLBALDH1A1LMNAMAPTGAA
SCHEMBL30203403 0.80 ALDH1A1 (0.56) POLBALDH1A1LMNAMAPTGAA
SCHEMBL422653 0.79 GAA (0.64) POLBLMNAMAPTGAAMEN1
SCHEMBL9068677 0.79 ALDH1A1 (0.54) POLBALDH1A1LMNAMAPTGAA
Methane SCHEMBL27588822 0.79 ALDH1A1 (0.54) POLBALDH1A1LMNAMAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026107406-A1 p53 HETEROBIFUNCTIONAL CONJUGATES AND USES THEREOF Design Therapeutics, Inc. (US) 2026-05-21 WO disclosed
EP-4323066-A1 MEK INHIBITORS AND USES THEREOF Ikena Oncology, Inc. (US) 2024-02-21 EP disclosed
CN-117580835-A MEK inhibitors and uses thereof 医肯纳肿瘤学公司 2024-02-20 CN disclosed
US-20230144211-A1 ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES BYONDIS B.V. (NL) 2023-05-11 US disclosed
WO-2022221866-A1 MEK INHIBITORS AND USES THEREOF Ikena Oncology, Inc. (US) 2022-10-20 WO disclosed
CN-108395435-B Triazolopyrimidine sulfonamide compound and preparation method and application thereof 深圳大学 2021-02-05 CN disclosed
CN-103626708-B A kind of sulfonylurea compound SHENZHEN UNIVERSITY (CN) 2016-01-20 CN disclosed
CN-103626708-A Novel sulfonylurea compound UNIV SHENZHEN 2014-03-12 CN disclosed
CN-103073507-A Sulfonylurea compound UNIV SHENZHEN 2013-05-01 CN disclosed
US-20100099662-A1 HYDRAZONE DERIVATIVE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-04-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230144211-A1 ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES DHFR, FOLR1, MTHFD2 POLB 2383/4885ALDH1A1 1219/4885VCAM1 787/4885
US-20100099662-A1 HYDRAZONE DERIVATIVE GCK, GCKR, HK1 POLB 3516/4885ALDH1A1 1260/4885VCAM1 3964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.